Peripheral Treatment with Enoxaparin, a Low Molecular Weight Heparin, Reduces Plaques and β-Amyloid Accumulation in a Mouse Model of Alzheimer's Disease

Journal of Neuroscience

Volumn 24, Issue 17, 2004, Pages 4181-4186

  Bergamaschini, Luigi ^a,c   Rossi, Emanuela ^a   Storini, Claudio ^b   Pizzimenti, Simone ^b   Distaso, Maria ^b   Perego, Carlo ^b   De Luigi, Ada ^b   Vergani, Carlo ^a   De Simoni, Maria Grazia ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

A ; Alzheimer; Amyloid; APP23 mouse; Binding agent; Complement system; Heparin; Inflammation; Kinin system; Low molecular weight heparin

Indexed keywords

AMYLOID BETA PROTEIN; ENOXAPARIN; GLIAL FIBRILLARY ACIDIC PROTEIN; KININ; LOW MOLECULAR WEIGHT HEPARIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN NERVE CELL; COMPLEMENT SYSTEM; CONTROLLED STUDY; CYTOTOXICITY; DISEASE COURSE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; INFLAMMATION; LONG TERM CARE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; SENILE PLAQUE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ASTROCYTES; CEREBRAL CORTEX; COMPLEMENT ACTIVATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENOXAPARIN; GLIAL FIBRILLARY ACIDIC PROTEIN; HEPARIN, LOW-MOLECULAR-WEIGHT; MALE; MICE; MICE, TRANSGENIC; NEURONS; PC12 CELLS; PEPTIDE FRAGMENTS; RATS; SENILE PLAQUES;

EID: 2442483898     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.0550-04.2004     Document Type: Article

References (53)

1. Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, Hyman BT (2002) Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by immunotherapy. J Neurosci 22:7873-7878.
2. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, et al. (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6:916-919.
3. Bayer TA, Schafer S, Simons A, Kemmling A, Kamer T, Tepests R, Eckert A, Schussel K, Eikenberg O, Sturchler-Pierrat C, Abramowski D, Staufenbiel M, Multhaup G (2003) Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice. Proc Natl Acad Sci USA 100:14187-14192.
4. Bazin HG, Marques MA, Owens III AP, Linhardt RJ, Crutcher KA (2002) Inhibition of apolipoprotein E-related neurotoxicity by glycosaminoglycans and their oligosaccharides. Biochemistry 41:8203-8211.
5. Bergamaschini L, Donarini C, Gobbo G, Parnetti L, Gallai V (2001a) Activation of complement and contact system in Alzheimer's disease. Mech Ageing Dev 122:1971-1983.
6. Bergamaschini L, Donarini C, Foddi C, Gobbo G, Parnetti L, Agostoni A (2001b) The region 1-11 of Alzheimer amyloid-beta is critical for activation of contact-kinin system. Neurobiol Aging 22:63-69.
7. Bergamaschini L, Donarini C, Rossi E, De Luigi A, Vergani C, De Simoni MG (2002) Heparin attenuates cytotoxic and inflammatory activity of Alzheimer amyloid-beta in vitro. Neurobiol Aging 23:531-536.
8. Berrettini M, Lammle B, White T, Heeb MJ, Schwarz HP, Zuraw B, Curd J, Griffin JH (1986) Detection of in vitro and in vivo cleavage of high molecular weight kininogen in human plasma by immunoblotting with monoclonal antibodies. Blood 68:455-462.
9. Bornemann KD, Staufenbiel M (2000) Transgenic mouse models of alzheimer's disease. Ann NY Acad Sci 908:260-266.
10. Calhoun ME, Wiederhold KH, Abramowski D, Phinney AL, Probst A, Sturchler-Pierrat C, Staufenbiel M, Sommer B, Jucker M (1998) Neuron loss in APP transgenic mice. Nature 395:755-756.
11. Chauhan NB, Siegel GJ (2002) Reversal of amyloid beta toxicity in Alzheimer's disease model Tg2576 by intraventricular anti-amyloid beta antibody. J Neurosci Res 69:10-23.
12. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98:8850-8855.
13. De Simoni MG, Perego C, Ravizza T, Moneta D, Conti M, Marchesi F, De Luigi A, Garattini S, Vezzani A (2000) Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus. Eur J Neurosci 12:2623-2633.
14. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 5:452-457.
15. Dodel R, Hampel H, Depboylu C, Lin S, Gao F, Schock S, Jackel S, Wei X, Buerger K, Hoft C, Hemmer B, Moller HJ, Farlow M, Oertel WH, Sommer N, Du Y (2002) Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol 52:253-256.
16. Dudas B, Cornelli U, Lee JM, Hejna MJ, Walzer M, Lorens SA, Mervis RF, Fareed J, Hanin I (2002) Oral and subcutaneous administration of the glycosaminoglycan C3 attenuates Abeta(25-35)-induced abnormal tau protein immunoreactivity in rat brain. Neurobiol Aging 23:97-104.
17. Farkas I, Takahashi M, Fukuda A, Yamamoto N, Akatsu H, Baranyi L, Tateyama H, Yamamoto T, Okada N, Okada H (2003) Complement C5a receptor-mediated signaling may be involved in neurodegeneration in Alzheimer's disease. J Immunol 170:5764-5771.
18. Giulian D, Haverkamp LJ, Yu J, Karshin W, Tom D, Li J, Kazanskaia A, Kirkpatrick J, Roher AE (1998) The HHQK domain of beta-amyloid provides a structural basis for the immunopathology of Alzheimer's disease. J Biol Chem 273:29719-29726.
19. Kalehua AN, Taub DD, Baskar PV, Hengemihle J, Munoz J, Trambadia M, Speer DL, De Simoni MG, Ingram DK (2000) Aged mice exhibit greater mortality concomitant to increased brain and plasma TNF-alpha levels following intracerebroventricular injection of lipopolysaccharide. Gerontology 46:115-128.
20. Kelly PH, Bondolfi L, Hunziker D, Schlecht HP, Carver K, Maguire E, Abramowski D, Wiederhold KH, Sturchler-Pierrat C, Jucker M, Bergmann R, Staufenbiel M, Sommer B (2003) Progressive age-related impairment of cognitive behavior in APP23 transgenic mice. Neurobiol Aging 24:365-378.
21. Kisilevsky R (1997) Can deposition of amyloid be prevented in Alzheimer's disease? Ann NY Acad Sci 826:117-127.
22. Kisilevsky R, Lemieux LJ, Fraser PE, Kong X, Hultin PG, Szarek WA (1995) Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat Med 1:143-148.
23. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M (2003) Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146-153.
24. Leveugle B, Scanameo A, Ding W, Fillit H (1994) Binding of heparin sulfate glycosaminoglycan to beta-amyloid peptide: inhibition by potentially therapeutic polysulfated compounds. NeuroReport 5:1389-1392.
25. Leveugle B, Ding W, Laurence F, Dehouck MP, Scanameo A, Cecchelli R, Fillit H (1998) Heparin oligosaccharides that pass the blood-brain barrier inhibit beta-amyloid precursor protein secretion and heparin binding to beta-amyloid peptide. J Neurochem 70:736-744.
26. Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe KH, Frautschy SA, Cole GM (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 20:5709-5714.
27. Ma Q, Dudas B, Hejna M, Cornelli U, Lee JM, Lorens S, Mervis R, Hanin I, Fareed J (2002) The blood-brain barrier accessibility of a heparin-derived oligosaccharides C3. Thromb Res 105:447-453.
28. Mackic JB, Stins M, McComb JG, Calero M, Ghiso J, Kim KS, Yan SD, Stern D, Schmidt AM, Frangione B, Zlokovic BV (1998) Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1-40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J Clin Invest 102:734-743.
29. Martel CL, Mackic JB, Matsubara E, Governale S, Miguel C, Miao W, McComb JG, Frangione B, Ghiso J, Zlokovic BV (1997) Isoform-specific effects of apolipoproteins E2, E3, and E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid beta. J Neurochem 69:1995-2004.
30. Matsuoka Y, Saito M, LaFrancois J, Gaynor K, Olm V, Wang L, Casey E, Lu Y, Shiratori C, Lemere C, Duff K (2003) Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to β-amyloid. J Neurosci 23:29-33.
31. McGeer PL, McGeer EG (2001) Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging 22:799-809.
32. McGeer PL, McGeer EG (2002) The possible role of complement activation in Alzheimer disease. Trends Mol Med 8:519-523.
33. Mohajeri MH, Saini K, Schultz JG, Wollmer MA, Hock C, Nitsch RM (2002) Passive immunization against beta-amyloid peptide protects central nervous system (CNS) neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation. J Biol Chem 277:33012-33017.
34. O'Barr S, Cooper NR (2000) The C5a complement activation peptide increases IL-lbeta and IL-6 release from amyloid-beta primed human monocytes: implications for Alzheimer's disease. J Neuroimmunol 109:87-94.
35. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173-177.
36. Shuvaev VV, Siest G (2000) Heparin specifically inhibits binding of apolipoprotein E to amyloid beta-peptide. Neurosci Lett 280:131-134.
37. Sigurdsson EM, Scholtzova H, Mehta PD, Frangione B, Wisniewski T (2001) Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol 159:439-447.
38. Strazielle N, Ghersi-Egea JF, Ghiso J, Dehouck MP, Frangione B, Patlak C, Fenstermacher J, Gorevic P (2000) In vitro evidence that beta-amyloid peptide 1-40 diffuses across the blood-brain barrier and affects its permeability. J Neuropathol Exp Neurol 59:29-38.
39. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B (1997) Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci USA 94:13287-13292.
40. Terryberry JW, Thor G, Peter JB (1998) Autoantibodies in neurodegenerative diseases: antigen-specific frequencies and intrathecal analysis. Neurobiol Aging 19:205-216.
41. Tyrrell DJ, Horne AP, Holme KR, Preuss JM, Page CP (1999) Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 46:151-208.
42. van Beek J, Elward K, Gasque P (2003) Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection. Ann NY Acad Sci 992:56-71.
43. van Horssen J, Wesseling P, van den Heuvel LP, de Waal RM, Verbeek MM (2003) Heparin sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders. Lancet Neurol 2:482-492.
44. Veerhuis R, Van Breemen MJ, Hoozemans JM, Morbin M, Ouladhadj J, Tagliavini F, Eikelenboom P (2003) Amyloid beta plaque-associated proteins C1q and SAP enhance the Abeta1-42 peptide-induced cytokine secretion by adult human microglia in vitro. Acta Neuropathol (Berl) 105:135-144.
45. Velazquez P, Cribbs DH, Poulos TL, Tenner AJ (1997) Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis. Nat Med 3:77-79.
46. Walzer M, Lorens S, Hejna M, Fareed J, Hanin I, Cornelli U, Lee JM (2002) Low molecular weight glycosaminoglycan blockade of beta-amyloid induced neuropathology. Eur J Pharmacol 445:211-220.
47. Watson DJ, Lander AD, Selkoe DJ (1997) Heparin-binding properties of the amyloidogenic peptides Abeta and amylin. Dependence on aggregation state and inhibition by Congo red. J Biol Chem 272:31617-31624.
48. Webster S, Bonnell B, Rogers J (1997a) Charge-based binding of complement component C1q to the Alzheimer amyloid beta-peptide. Am J Pathol 150:1531-1536.
49. Webster S, Lue LF, Brachova L, Tenner AJ, McGeer PL, Terai K, Walker DG, Bradt B, Cooper NR, Rogers J (1997b) Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol Aging 18:415-421.
50. Wyss-Coray T, Yan F, Lin AH, Lambris JD, Alexander JJ, Quigg RJ, Masliah E (2002) Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci USA 99:10837-10842.
51. Yasuhara O, Walker DG, McGeer PL (1994) Hageman factor and its binding sites are present in senile plaques of Alzheimer's disease. Brain Res 654:234-240.
52. Zhu H, Yu J, Kindy MS (2001) Inhibition of amyloidosis using low-molecular-weight heparins. Mol Med 7:517-522.
53. Zlokovic BV, Ghiso J, Mackic JB, McComb JG, Weiss MH, Frangione B (1993) Blood-brain barrier transport of circulating Alzheimer's amyloid beta. Biochem Biophys Res Commun 197:1034-1040.